NCT07398001Not yet recruiting
Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment
Source: ClinicalTrials.gov · Last updated 9 Feb 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the benefits and risks of discontinuing antiplatelet therapy on clinical outcomes in patients who previously underwent coronary intervention using a drug-coated balloon. The main questions it aims to answer are: Does stopping antiplatelet therapy after 12 months affect the risk of net adverse clinical events? Does stopping antiplatelet therapy reduce the risk of bleeding compared with continuing treatment? Researchers will compare patients who discontinue antiplatelet therapy with patients who continue antiplatelet therapy to determine the impact on clinical outcomes during follow-up. Participants will: Be randomly assigned to either discontinue or continue antiplatelet therapy Receive routine clinical follow-up through clinic visits or telephone contacts Be monitored for cardiovascular events and bleeding outcomes over time
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1042 (estimated)
- First submitted
- 20 Jan 2026
- Start date
- 12 Feb 2026
- Primary completion date
- 11 Feb 2028
- Lead sponsor
- Ulsan University Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07398001
What you commit to
- Study type: Interventional
- Planned participants: 1042
- From 12 Feb 2026 to the primary completion date, 11 Feb 2028
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with concomitant vascular disease requiring long-term antiplatelet therapy.
- Patients who are participating in another drug or coronary device clinical study at the time of enrollment.
Other illness
- Patients with non-cardiac comorbid conditions that, in the judgment of the investigator, are associated with a life expectancy of less than 1 year or may result in poor compliance with the study protocol.
Who the study is looking for
- Adults aged 19 years or older who are able to understand the risks, benefits, and treatment alternatives of the study and who provide written informed consent voluntarily.
- Patients who underwent drug-coated balloon treatment at least 12 months prior to enrollment.
- Patients who have not experienced major adverse cardiovascular events, including myocardial infarction, stroke, or target vessel revascularization, since the index DCB treatment.
- Patients who have not experienced major bleeding since the index DCB treatment.
- Patients who are receiving antiplatelet therapy at the time of enrollment.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Korea University Ansan Hospital Coordinator of this site? Confirm its status | Ansan | South Korea | Unknown status |
| Kangwon National University Hospital Coordinator of this site? Confirm its status | Chuncheon | South Korea | Unknown status |
| Kosin University Hospital Coordinator of this site? Confirm its status | Pusan | South Korea | Unknown status |
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| Korea University Guro Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| Ulsan University Hospital Coordinator of this site? Confirm its status | Ulsan | South Korea | Unknown status |
| Ulsan Medical Center Coordinator of this site? Confirm its status | Ulsan | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.